Compare Main Street Capital Corporation (MAIN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Summit Therapeutics Inc — how do they compare? Main Street Capital Corporation trades at $58.46 (market cap $5.52B), while Summit Therapeutics Inc trades at $15.21 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 2.2× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 5.39% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MAIN | SMMT | |
|---|---|---|
Market Cap | $5.52B | $12.06B |
Sector | Financials | Health |
52-Week High | $67.54 | $26.98 |
52-Week Low | $49.63 | $12.55 |
Dividend Yield | 5.39% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAIN trades at $58.48, down slightly by 0.07% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q2 2026 EPS of $0.97, beating estimates, though Q1 was a miss. Revenue has grown from $318M in 2022 to $592M in 2025, with net income margins above 80%. Recent news highlights MAIN's dividend reliability amid sector challenges, with multiple dividends declared for 2026.
Outlook remains positive given strong profitability and dividend consistency, but risks include expense pressures and sector volatility. Analysts are mostly neutral with a consensus price target of $56.67, below the current price, suggesting limited near-term upside. The stock's high valuation multiples and overbought technicals warrant caution despite solid fundamentals.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
